NCT00430924

Inhibition of Aldosterone in Patients With Chronic Renal Disease

The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Lene Boesby · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered, progression of renal disease with be slower than otherwise expected.

Detailed description

Patients with chronic renal disease are likely to progress to end stage renal disease with the need for renal replacement therapy. It is accepted that proteinuria is a surrogate measurement for progression. If proteinuria can be lowered we hope to prolong patients pre-dialysis phase. Our theory is that aldosterone inhibition will lead to this. For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without. Blood pressures will be kept at the same level using other drugs.

Conditions

• Kidney Failure, Chronic

Interventions

Type	Name	Description
DRUG	Eplerenone	Once daily administration for 8 weeks and 8 weeks control.

Timeline

• Start date: 2007-03-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2007-02-02
• Last updated: 2012-02-08

Locations

2 sites across 1 country: Denmark